Cargando…

Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series

Adults with sickle cell disease can develop pulmonary hypertension from a multitude of etiologies. Classified as WHO Group 5, there are no therapies approved for the treatment of sickle cell disease-pulmonary hypertension. Thromboembolic disease is prevalent in sickle cell disease and can lead to pu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weir, Nargues A., Conrey, Anna, Lewis, Denise, Mehari, Alem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083805/ https://www.ncbi.nlm.nih.gov/pubmed/30033820 http://dx.doi.org/10.1177/2045894018791802

Ejemplares similares

Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy
por: Donaldson, Sahai, et al.
Publicado: (2020)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series
por: Balasubramanian, Vijay P., et al.
Publicado: (2020)

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
por: van Thor, M.C.J., et al.
Publicado: (2019)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
por: Sulica, Roxana, et al.
Publicado: (2015)

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
por: Wiedenroth, Christoph B., et al.
Publicado: (2018)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Increased Arterial Stiffness in Chronic Thromboembolic Pulmonary Hypertension Was Improved with Riociguat and Balloon Pulmonary Angioplasty: A Case Report
por: Sato, Shuji, et al.
Publicado: (2021)

Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis
por: Ying, Miaofa, et al.
Publicado: (2021)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Combination of rescue balloon pulmonary angioplasty and riociguat therapy for chronic thromboembolic pulmonary hypertension with nonsustained polymorphic ventricular tachycardia: A case report
por: Fukuda, Yoshitake, et al.
Publicado: (2023)

Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice
por: Michaličková, Danica, et al.
Publicado: (2020)

Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta‐analysis
por: Wang, Wuwan, et al.
Publicado: (2019)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study
por: Kawakami, Takashi, et al.
Publicado: (2020)

Riociguat inhibits ultra‐large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients
por: Jujo Sanada, Takayuki, et al.
Publicado: (2022)

Pulmonary Embolism and Chronic Superior Vena Cava Occlusion Complicating Central Line-Associated Venous Thromboembolism in a Sickle Cell Disease Patient
por: Brgdar, Ahmed, et al.
Publicado: (2022)

Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat
por: Smith, Zachary R, et al.
Publicado: (2016)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension
por: Kenny, Marianne, et al.
Publicado: (2020)

Chronic Thromboembolic Pulmonary Hypertension in a Child With Sickle Cell Disease
por: Spencer, Robert, et al.
Publicado: (2020)

Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial
por: Zhao, Qin-Hua, et al.
Publicado: (2021)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
por: García Aguilar, Humberto, et al.
Publicado: (2022)

Safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in real-world clinical practice: interim data from post-marketing surveillance in Japan
por: Tanabe, Nobuhiro, et al.
Publicado: (2020)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension
por: Spreemann, Till, et al.
Publicado: (2017)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
por: Lian, Tian-Yu, et al.
Publicado: (2017)

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
por: Taran, Irina N., et al.
Publicado: (2018)

Chronic Thromboembolic Pulmonary Hypertension: the Bedside
por: Matusov, Yuri, et al.
Publicado: (2021)

A Case of Chronic Thromboembolic Pulmonary Hypertension
por: Jin, Xin, et al.
Publicado: (2012)

Anthracofibrosis mimicking chronic thromboembolic pulmonary hypertension
por: Van Genechten, Silke, et al.
Publicado: (2023)

A case of sarcoidosis-associated pulmonary hypertension masquerading as chronic thromboembolic pulmonary hypertension
por: Bazmpani, Maria Anna, et al.
Publicado: (2018)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
por: Mihalek, Andrew D, et al.
Publicado: (2022)

Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
por: Poch, David S.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jqgqq8slab7ah6cbs8r50gkhk0